QOLP-15. SAFETY AND ADVERSE EVENT PROFILE OF TUMOR TREATING FIELDS IN ANAPLASTIC GLIOMA A POST-MARKETING SURVEILLANCE ANALYSIS

摘要

INTRODUCTIONTumor Treating Fields (TTFields) are approved for glioblastoma (GBM) based on two randomized phase 3 trials. The Optune system non-invasively administers TTFields at 200kHz via transducer arrays placed upon a shaved scalp. Despite advancements in the molecular characterization of anaplastic gliomas (AGs), there remains a paucity of treatment options. While Optune is not FDA-approved for AGs, there are several open clinical trials. To further characterize potential safety risks in AG, post-marketing surveillance data are reported for patients with AGs treated with TTFields.